Quince Therapeutics Inc
QNCX3.650USD
+0.080+2.24%
Close 12/22, 16:00（ET）Quotes delayed by 15 min
198.91MMarket Cap
LossP/E TTM
More Details of Quince Therapeutics Inc Company
Quince Therapeutics, Inc. is a late-stage biotechnology company. The Company is engaged in unlocking the patient’s own biology to deliver life-changing therapeutics to those living with rare diseases. Its proprietary autologous intracellular drug encapsulation (AIDE) technology platform is a drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. The Company’s Phase III lead asset, eDSP, leverages its AIDE technology to encapsulate dexamethasone sodium phosphate (DSP) into a patient’s own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). Its AIDE technology is designed to allow for the chronic administration of drugs that have limitations due to toxicity, poor biodistribution, suboptimal pharmacokinetics, or immune response. The AIDE technology platform delivers a variety of therapeutics, ranging from small to large molecules drugs and biologics.
Quince Therapeutics Inc Info
Ticker SymbolQNCX
Company nameQuince Therapeutics Inc
IPO dateMay 09, 2019
CEOThye (Dirk)
Number of employees36
Security typeOrdinary Share
Fiscal year-endMay 09
Address601 Gateway Boulevard, Suite 1250
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone14159105717
Websitehttps://quincetx.com/
Ticker SymbolQNCX
IPO dateMay 09, 2019
CEOThye (Dirk)
Company Executives of Quince Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
1.01M
+17.55%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
369.94K
+8.05%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
130.01K
+6.16%
Dr. Luca Benatti, Ph.D.
Dr. Luca Benatti, Ph.D.
Independent Director
Independent Director
80.26K
--
Mr. David A. Lamond, J.D.
Mr. David A. Lamond, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
Mr. Christopher J. Senner, CPA
Mr. Christopher J. Senner, CPA
Independent Director
Independent Director
--
--
Dr. Rajiv Patni, M.D.
Dr. Rajiv Patni, M.D.
Independent Director
Independent Director
--
--
Dr. Una Ryan, OBE
Dr. Una Ryan, OBE
Lead Independent Director
Lead Independent Director
--
--
Dr. Margaret A. Mcloughlin, Ph.D.
Dr. Margaret A. Mcloughlin, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Dirk Thye, M.D.
Dr. Dirk Thye, M.D.
Chief Executive Officer, Chief Medical Officer, Director
Chief Executive Officer, Chief Medical Officer, Director
1.01M
+17.55%
Mr. Brendan Hannah
Mr. Brendan Hannah
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
Chief Operating Officer, Chief Compliance Officer, Chief Business Officer
369.94K
+8.05%
Dr. Charles S. Ryan, Ph.D.
Dr. Charles S. Ryan, Ph.D.
President
President
130.01K
+6.16%
Dr. Luca Benatti, Ph.D.
Dr. Luca Benatti, Ph.D.
Independent Director
Independent Director
80.26K
--
Mr. David A. Lamond, J.D.
Mr. David A. Lamond, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. June Bray
Ms. June Bray
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Lamond (David A.)
7.87%
Nantahala Capital Management, LLC
5.52%
The Vanguard Group, Inc.
3.17%
Millennium Management LLC
2.49%
Sofinnova Partners
2.15%
Other
78.80%
Shareholders
Shareholders
Proportion
Lamond (David A.)
7.87%
Nantahala Capital Management, LLC
5.52%
The Vanguard Group, Inc.
3.17%
Millennium Management LLC
2.49%
Sofinnova Partners
2.15%
Other
78.80%
Shareholder Types
Shareholders
Proportion
Hedge Fund
10.78%
Individual Investor
9.42%
Investment Advisor
7.76%
Venture Capital
2.49%
Family Office
1.76%
Investment Advisor/Hedge Fund
1.70%
Research Firm
0.30%
Bank and Trust
0.02%
Other
65.77%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
87
9.53M
17.73%
-1.73M
2025Q2
97
15.41M
33.89%
-3.19M
2025Q1
103
15.28M
33.71%
-3.42M
2024Q4
110
16.30M
37.03%
-3.29M
2024Q3
128
15.88M
36.71%
-1.87M
2024Q2
148
16.69M
38.64%
-2.87M
2024Q1
198
17.67M
40.98%
-3.53M
2023Q4
217
17.25M
42.40%
-4.99M
2023Q3
271
15.70M
40.68%
-12.96M
2023Q2
273
16.49M
45.87%
-11.39M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Lamond (David A.)
4.38M
8.16%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
2.53M
4.71%
+2.53M
--
Jun 30, 2025
The Vanguard Group, Inc.
1.45M
2.71%
+168.26K
+13.09%
Jun 30, 2025
Sofinnova Partners
1.20M
2.23%
-1.20M
-50.05%
Mar 31, 2025
IEQ Capital LLC
439.27K
0.82%
-367.51K
-45.55%
Jun 30, 2025
EPIQ Capital Group, LLC
824.78K
1.54%
-1.16K
-0.14%
Dec 31, 2024
Adar1 Capital Management LLC
142.96K
0.27%
--
--
Jun 30, 2025
Renaissance Technologies LLC
379.80K
0.71%
-120.11K
-24.03%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Quince Therapeutics Inc?
The top five shareholders of Quince Therapeutics Inc are:
Lamond (David A.) holds 4.38M shares, accounting for 8.16% of the total shares.
Nantahala Capital Management, LLC holds 2.53M shares, accounting for 4.71% of the total shares.
The Vanguard Group, Inc. holds 1.45M shares, accounting for 2.71% of the total shares.
Sofinnova Partners holds 1.20M shares, accounting for 2.23% of the total shares.
IEQ Capital LLC holds 439.27K shares, accounting for 0.82% of the total shares.
Lamond (David A.) holds 4.38M shares, accounting for 8.16% of the total shares.
Nantahala Capital Management, LLC holds 2.53M shares, accounting for 4.71% of the total shares.
The Vanguard Group, Inc. holds 1.45M shares, accounting for 2.71% of the total shares.
Sofinnova Partners holds 1.20M shares, accounting for 2.23% of the total shares.
IEQ Capital LLC holds 439.27K shares, accounting for 0.82% of the total shares.
What are the top three shareholder types of Quince Therapeutics Inc?
The top three shareholder types of Quince Therapeutics Inc are:
Lamond (David A.)
Nantahala Capital Management, LLC
The Vanguard Group, Inc.
Lamond (David A.)
Nantahala Capital Management, LLC
The Vanguard Group, Inc.
How many institutions hold shares of Quince Therapeutics Inc (QNCX)?
As of 2025Q3, 87 institutions hold shares of Quince Therapeutics Inc, with a combined market value of approximately 9.53M, accounting for 17.73% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -16.16%.
What is the biggest source of revenue for Quince Therapeutics Inc?
In --, the -- business generated the highest revenue for Quince Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
